Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study-Reference-Cited by-同舟云学术

Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study

Published:2016-03 Issue:3 Volume:16 Page:129-138
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Berdeja Jesus,Jagannath Sundar,Zonder Jeffrey,Badros Ashraf,Kaufman Jonathan L.,Manges Robert,Gupta Manish,Tendolkar Amol,Lynch Mark,Bleickardt Eric,Paliwal Prashni,Vij Ravi

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference27 articles.

1. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma;Clark;Blood Rev,1999

2. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution;Blade;Arch Intern Med,1998

3. Current approach to diagnosis and management of acute renal failure in myeloma patients;Leung;Adv Chronic Kidney Dis,2012

4. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study;San-Miguel;Leukemia,2008

5. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance;Eleutherakis-Papaiakovou;Leuk Lymphoma,2007

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and Pharmacodynamics of Therapeutic Proteins and Nucleic Acids;Pharmaceutical Biotechnology;2024

2. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group;The Lancet Oncology;2023-07

3. Physiologic Changes During Pregnancy and Impact on Small‐Molecule Drugs, Biologic (Monoclonal Antibody) Disposition, and Response;The Journal of Clinical Pharmacology;2023-06

4. SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy;Frontiers in Immunology;2023-05-11

5. Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review;Clinical Lymphoma Myeloma and Leukemia;2023-05